Neuropsychological profiles of vascular disease and risk of dementia: implications for defining vascular cognitive impairment no dementia (VCI-ND) by Stephan, BCM et al.
Age and Ageing 2017; 0: 1–6
doi: 10.1093/ageing/afx016
© The Author 2017. Published by Oxford University Press on behalf of the British Geriatrics Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution,
and reproduction in any medium, provided the original work is properly cited.
Neuropsychological proﬁles of vascular disease
and risk of dementia: implications for deﬁning
vascular cognitive impairment no dementia
(VCI-ND)
BLOSSOM CHRISTA MAREE STEPHAN1, THAIS MINETT2, GRACIELA MUNIZ-TERRERA3, STEPHANIE L HARRISON1,
FIONA E MATTHEWS4, CAROL BRAYNE2
1Newcastle University – Newcastle University Institute for Ageing and Institute of Health and Society, Newcastle upon Tyne,
Tyne and Wear, UK
2University of Cambridge – Institute of Public Health, Cambridge, UK
3University of Edinburgh – Centre for Dementia Prevention, Edinburgh, Scotland
4MRC Biostatistics Unit – University of Cambridge, Cambridge CB2 2SR, UK
Address correspondence to: B. C. M. Stephan. Tel: +44 (0)191 208 3811; Fax: +44 (0)191 208 1101.
Email: blossom.stephan@ncl.ac.uk
Abstract
Background: vascular cognitive impairment no dementia (VCI-ND) deﬁnes a preclinical phase of cognitive decline associated
with vascular disorders. The neuropsychological proﬁle of VCI-ND may vary according to different vascular conditions.
Objective: to determine the neuropsychological proﬁle of individuals with no dementia and vascular disorders, including
hypertension, peripheral vascular disease (PVD), coronary heart disease (CHD), diabetes and stroke. Risk of 2-year incident
dementia in individuals with disease and cognitive impairment was also tested.
Methods: participants were from the Cognitive Function and Ageing Study. At baseline, 13,004 individuals aged ≥65 years
were enrolled into the study. Individuals were grouped by baseline disorder status (present, absent) for each condition.
Cognitive performance was assessed using the Mini Mental State Examination (MMSE) and the Cambridge Cognitive
Examination (CAMCOG). Dementia was assessed at 2 years.
Results: in the cross-sectional analysis, hypertension, PVD and CHD were not associated with cognitive impairment.
Stroke was associated with impaired global (MMSE) and CAMCOG sub-scale (including memory and non-memory) scores.
Diabetes was associated with impairments in global cognitive function (MMSE) and abstract thinking. In the longitudinal
analysis, cognitive impairments were associated with incident dementia in all groups.
Conclusion: the neuropsychological proﬁle in individuals with vascular disorders depends on the speciﬁc condition investi-
gated. In all conditions cognitive impairment is a risk factor for dementia. A better understanding of which cognitive
domains are affected in different disease groups could help improve operationalisation of the neuropsychological criteria for
VCI-ND and could also aid with the development of dementia risk prediction models in persons with vascular disease.
Keywords: vascular cognitive impairment no dementia, vascular disease, cognition, dementia risk, epidemiology, older people
Introduction
Cognitive impairment secondary to the onset of vascular
disorders has been termed vascular cognitive impairment
(VCI) [1–3]. Clinically VCI can manifest as vascular dementia
(either pure or mixed with Alzheimer’s pathology) or as vascu-
lar cognitive impairment no dementia (VCI-ND), a prodromal
condition associated with increased dementia risk [4]. The
underlying causes of vascular disorders have different patho-
logical mechanisms (such as embolic and thrombotic infarcts,
haemorrhagic strokes, small vessel disease) and the presence
of co-morbidities such as AD pathology. Such heterogeneity
makes VCI difﬁcult to diagnose added to the fact that no
standardised operational criteria exist.
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Cerebrovascular diseases have been shown to be usually
associated with cognitive impairment related to fronto-cortical
connections, including executive function and speed, rather
than being memory related as typically seen in AD [5].
However, this pattern is not always observed, and cognitive
changes associated with VCI can be variable. For example, in
individuals with stroke impairment in global functioning,
memory and non-memory domains have all been observed
[6, 7]. In stroke patients the pattern of cognitive impairment
may depend on the location and severity of infarction. With
regard to hypertension, one study found impaired long-term
memory and executive functioning in hypertensive cases [8],
in another study hypertension was found to be associated with
memory performance in men only [9], in a third study [10] no
cognitive differences were found when non-hypertensive and
medicated hypertensive groups were compared and lastly, in a
fourth study longitudinal evidence suggested an association
between hypertension and cognitive decline at mid-life, but
not in late-life [11]. In individuals with diabetes cognitive
impairment has been observed in global function, memory
and non-memory (including executive and speed) domains
[12, 13]. Peripheral vascular disease (PVD) and coronary heart
disease (CHD) have also been associated with cognitive
impairments across a variety of domains [14].
As highlighted in the paragraph above, no consistent
pattern of cognitive impairment has been observed across
different vascular conditions. Cognitive performance has
not been compared within the same cohort for different
vascular conditions using a population representative frame-
work. This study therefore addresses this gap. A better
understanding of the clinical features associated with differ-
ent health conditions is important for the development of
patient assessment protocols (i.e. in particular, for inform-
ing diagnostic criteria for VCI) and considerations for inter-
vention; for example, not only health but also cognition.
The aim of this study is to assess risk of cognitive impair-
ment in both global and domain-speciﬁc tasks and risk of
2-year incident dementia in individuals with vascular-related
co-morbidities, including hypertension, PVD, CHD, dia-
betes and stroke.
Methods
Participants
Data were from the Cognitive Function and Ageing Study
(CFAS) [15]. Individuals aged ≥65 years were randomly
selected from the Family Health Service Authority lists in
Cambridgeshire, Gwynedd, Newcastle, Nottingham and
Oxford. Baseline interviewing began in 1991. A two-phased
screening procedure was used. At baseline screening, 13,004
participants provided information on socio-demographic sta-
tus, health, functional ability and cognitive performance mea-
sured using the Mini Mental State Examination (MMSE) [16].
Selected items from the Geriatric Mental State (GMS)
Automated Geriatric Examination for Computer-Assisted
Taxonomy (AGECAT) [17] were also administered. All
interviews were undertaken at the participants’ place of resi-
dence by a trained interviewer.
Following the baseline interview, a sub-sample of
approximately 20% (n = 2,640) were selected based on cog-
nitive ability, age and centre (weighted towards older and
more cognitively frail individuals) to complete a more
detailed assessment (the B3 version of the full GMS which
has AGECAT algorithms used for automated study diagno-
sis), the Cambridge Cognitive Examination (CAMCOG)
(augmented) and repeat cognitive testing using the MMSE.
Participants were re-interviewed approximately every 2
years. Local Research Ethics Committee approval was
attained at each study site. All participants gave informed
consent before interview.
Dementia status
Dementia diagnosis is based on the full AGECAT diagnos-
tic algorithm, deﬁned as an organicity rating case level of 3
or above [17] which is similar to a diagnosis based on the
Diagnostic and Statistical Manual (DSM) 3rd Revision [18].
Dementia was diagnosed independently of the MMSE and
CAMCOG results.
Health status
From the baseline interview ﬁve conditions that have been
associated with an increase in prevalence in older aged
populations were selected, including hypertension, PVD,
CHD, diabetes and a history of stroke. Hypertension, stroke
and diabetes were assessed using participant self-report.
Participants reporting currently receiving medication for
hypertension were coded as having the disorder. For dia-
betes, participants who reported the condition or taking
anti-diabetic medication were coded as having diabetes.
Stroke was assessed using a single question asking about
the presence or absence of the condition. Angina and PVD
were derived from Diagnostic Scales [19]. CHD was a com-
posite variable incorporating the presence of self-reported
heart attack (single question asking about the presence or
absence of the condition) or angina based on the Rose
Diagnostic Scale.
Neuropsychological evaluation
Global cognitive function was assessed using the MMSE
(range 0–30) and the total score on the CAMCOG (range
0–103). Domain-speciﬁc performance was measured using
the CAMCOG sub-scales, including orientation, language
(comprehension, expression), perception, memory (learning,
recent, remote), praxis, abstract thinking and attention and cal-
culation. Scores for the MMSE and CAMCOG were dichoto-
mised into impaired versus not-impaired. For the CAMCOG
total and sub-scales scores, impairment was deﬁned as a score
below the 25th percentile on each scale using normative
values derived in non-demented individuals [20]. For the
MMSE, scores less than 24 were taken to reﬂect impair-
ment [21].
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Analysis
Prevalence of the disorder and no-disorder groups for people
without dementia across the ﬁve conditions was calculated,
weighted for study design. Across the ﬁve conditions differ-
ences in demographics between the disorder and no-disorder
groups were compared using t-tests (continuous variables) or
the chi-squared test (categorical variables). Logistic regression
(weighted for study design) controlling age, sex, years of edu-
cation and disease co-morbidity was used to estimate the
odds ratios (ORs) for cognitive impairment (MMSE and
CAMCOG scores) across each of the ﬁve health conditions.
The disease co-morbidity score was calculated as the sum of
the conditions minus the disease of interest [22].
Associations between the cognitive test scores and 2-year
risk of dementia in each disorder group were tested using
Poisson regression controlling age, sex, years of education
and disease co-morbidity. For persons with dementia time
was deﬁned as the mid-point between the ﬁrst assessment
and the 2-year follow-up interview. To adjust for oversam-
pling of individuals aged 75 and older and sampling to the
diagnostic interview, all results were backweighted according
to age, sampling group at screening and interview version
using inverse probability weights. Loss to follow-up was also
adjusted for in the analysis. All analyses were completed using
STATAVersion 14.
Results
Demographics Of the 2,640 individuals seen at the ﬁrst
assessment 587 were diagnosed with dementia and were
excluded. Prevalence varied across the different conditions:
27.5% (95% CI: 24.9–30.1) reported hypertension, 21.4%
(95% CI: 19.1–23.9) CHD, 7.3% (95% CI: 6.0–8.8) stroke,
5.2% (95% CI: 4.1–6.6) diabetes and 4.4% (95% CI: 3.4–
5.9) PVD. Table 1 shows the demographic proﬁles of the
disorder and no-disorder groups for each condition in indi-
viduals without dementia. Individuals with hypertension (P
= 0.004) and stroke (P = 0.032) were more likely to be
women, and for PVD there were more men (P = 0.002).
Only hypertension showed a signiﬁcant age difference; peo-
ple with hypertension were younger than those with no his-
tory of hypertension (P = 0.002). No signiﬁcant difference
in educational level was found between the disorder present
and absent groups for any conditions.
Of the 2,050 individuals without dementia at the ﬁrst
assessment 49.8% (n = 1,021) had none of the ﬁve condi-
tions, 29.7% (n = 608) had one condition, 13.4% (n = 274)
had two conditions, 2.9% (n = 61) had three conditions,
0.5% (n = 10) had four conditions and 3.7% (n = 76) were
missing disease status information for one or more of the
conditions. Table 2 shows the pattern of disease co-
morbidity across the different conditions.
Cognitive Function Cross-sectional Results Supplementary
data, Table 1, available in Age and Ageing online displays the ORs
and 95% conﬁdence intervals (CIs) for each of the cognitive
variables predicted by each health condition when adjusting
for age, sex, education and disease co-morbidity. The pattern
of cognitive impairments varied across the different condi-
tions. Hypertension, PVD and CHD were not associated with
impairment on any measure. In contrast, compared to partici-
pants without diabetes, those with diabetes were more likely to
be impaired on the MMSE (OR = 1.66; 95% CI: 1.00–2.76)
and CAMCOG sub-scale score of abstract thinking (OR =
1.78; 95% CI: 1.01–3.15). Participants with stroke performed
signiﬁcantly worse than those without stroke on the
CAMCOG sub-scale scores of orientation (OR = 2.25; 95%
CI: 1.40–3.61), language comprehension (OR = 1.80; 95% CI:
1.10–2.95), learning memory (OR = 1.67; 95% CI: 1.05–2.65),
praxis (OR = 1.64; 95% CI: 1.03–2.62) and perception (OR =
1.74; 95% CI: 1.02–2.98).
Two-year Incident Dementia: Of the 2,050 individuals
without dementia seen at the ﬁrst assessment, at 2-year follow-
up 230 had died, 440 refused or were lost to follow-up and
26 had moved. Dementia status at 2 years was known in
1,347 individuals: 1,210 non-demented and 137 with inci-
dent dementia. Table 3 shows the results of the association
between cognitive function and risk of dementia, when con-
trolling age, sex, education and disease co-morbidity for
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Sample demographics stratiﬁed by the presence/absence of the condition (non-demented individuals)
Hypertension PVD CHD Diabetes Stroke
Absent Present Absent Present Absent Present Absent Present Absent Present
na 1,450 576 1,904 87 1,567 450 1,904 129 1,836 197
Mean age (SD) 76.1 (7.4) 74.8 (6.5) 75.6 (7.3) 75.9 (6.8) 75.6 (7.3) 75.8 (7.1) 75.7 (7.3) 75.6 (6.2) 75.7 (7.3) 76.2 (6.9)
% Women (n) 61.0 (885) 67.9 (391) 63.6 (1210) 47.1 (41) 64.0 (1003) 59.1 (266) 63.1 (1201) 60.5 (78) 63.6 (1168) 55.8 (110)
Mean years full-time
education (SD)
9.7 (2.1) 9.6 (2.0) 9.7 (2.1) 9.4 (1.3) 9.7 (2.1) 9.6 (1.9) 9.7 (2.1) 9.7 (1.7) 9.7 (2.1) 9.5 (2.0)
aNote that the total number of participants in the CFAS assessment arm with no dementia was 2,050.
Note: Bold indicates signiﬁcant differences between those with and without the condition.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Pattern of disease co-morbidity (number) across
the different conditions
Hypertension PVD CHD Diabetes Stroke
Hypertension (n = 576) 29 168 56 98
PVD (n = 87) 40 11 16
CHD (n = 450) 40 69
Diabetes (n = 129) 19
Stroke (n = 197)
Cognitive function and vascular disease
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each condition. As shown, in individuals with hypertension
impairments in the MMSE and CAMCOG sub-scales of
orientation and learning memory were associated with risk
of dementia. In individuals with PVD impairments in the
CAMCOG sub-scales of language expression and abstract
thinking were associated with risk of dementia. In indivi-
duals with CHD impairments in the MMSE, CAMCOG
total and sub-scale scores of memory (recent and learning),
attention and calculation and praxis were associated with
risk of dementia. In individuals with diabetes impairments in
the MMSE, CAMCOG total score and CAMCOG sub-
scales of orientation, language expression, memory (remote
and learning), praxis and perception were associated with
risk of dementia. In individuals with stroke, cognitive impair-
ment in the MMSE, CAMCOG total score and CAMCOG
sub-scales of language expression, memory (remote, recent
and learning), attention and calculation and praxis were asso-
ciated with risk of dementia.
Discussion
In this population-based study we found that different vascu-
lar disorders were associated with different patterns of cogni-
tive impairment and that the extent of cognitive impairment
increased with the severity of vascular dysfunction. There
was little evidence that hypertension, CHD or PVD were
associated with an increased risk of cognitive impairment. In
contrast, diabetes was signiﬁcantly associated with impaired
global cognitive function (MMSE score) and the CAMCOG
sub-scale score of abstract thinking. Cognitive impairment
was most apparent in individuals with stroke. In contrast, in
longitudinal analyses, risk of dementia was associated with
cognitive impairments at baseline in all groups; although dif-
ferent patterns of impairment were associated with dementia
risk across the different conditions. The results have implica-
tions for how VCI-ND should be operationalised, particularly
in terms of the choice of domains of cognitive functioning
that should be assessed across different conditions.
Considerable debate exists regarding the nature of the
cognitive deﬁcits associated with VCI-ND. Even in the
absence of dementia and when controlling covariates, in
cross-sectional analyses, we found that diabetes is asso-
ciated with global deﬁcits and impaired abstract thinking
and that stroke is associated with impairment across mul-
tiple domains, including global, memory and non-memory.
Hypertension, PVD and CHD were not found to be asso-
ciated with impairments in the MMSE or CAMCOG total
or sub-scale scores. These results support ﬁndings from
some, but not all studies. Differences across studies could
be explained by methodological differences including, for
example, choice of cognitive tests, deﬁnition of disease and
sample speciﬁc characteristics (e.g. population-based versus
clinical). Further exploration of the pattern of preservation
and impairment across different cognitive domains and vas-
cular conditions is needed.
The underlying mechanism by which vascular disease
affects cognitive performance is poorly understood. The.
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cognitive-disorder associations observed here do not appear
to be due to a reduction in reserve, associated for example
with educational attainment, as this did not differ signiﬁ-
cantly in the disorder and no-disorder groups for each con-
dition and was controlled in the analyses. It could be that
cognitive decline may be associated with impaired vascular
function and future studies are needed to test the associ-
ation between cognitive decline and incident disease.
Alternatively, results suggest that changes may be linked to
the speciﬁc vascular disorder. It could be that the effects of
each vascular condition on cognition are related to their
underlying pathogenesis as well as on the anatomical loca-
tion of the vascular damage. For example, hypertension is a
risk factor for the more severe conditions included in this
analysis [23]. Hypertension increases atherosclerotic risk
and is a major risk factor for heart attack and ischaemic
stroke through the disruption of normal blood ﬂow [24]. In
addition, high blood pressure is a primary risk factor for
haemorrhagic stroke due to the increased vascular susceptibil-
ity to rupture in the brain [25]. CHD is characterised by a
greater vascular pathology but the organ speciﬁcity of vascular
dysfunction in CHD may have a sparing effect on the brain
vascular system and may explain the lower impact on cognitive
function compared to stroke patients [26, 27]. Insulin resist-
ance and chronic hyperglycaemia are major features of type 2
diabetes, which may alter the normal regulation of blood ﬂow
and modify neuronal cellular metabolism [28]. All the previous
conditions increase the risk of stroke, which may therefore
represent the ﬁnal outcome of the cumulative effects of vascu-
lar and metabolic dysfunction on the brain and explain the
greater impact of stroke on cognition.
Results from the longitudinal analysis found that different
cognitive impairments were associated with risk of 2-year
incident dementia across the different conditions. Of note is
that while in the cross-sectional analysis the disease and no-
disease groups did not differ signiﬁcantly on any cognitive
measure for hypertension, PVD and CHD, in the longitu-
dinal analysis we found that impaired cognition in the pres-
ence of disease was associated with an increased risk of
2-year incident dementia compared to persons with disease
but no cognitive impairment. Importantly, cognitive mea-
sures may be incorporated into prediction models to better
determine who has the highest risk of dementia amongst
persons with cardio-metabolic diseases. Further, these may
be targets to prevent further cognitive decline and progres-
sion to dementia in persons with co-morbid vascular disease.
This study is limited by the use of self-reported disease sta-
tus. However, self-reported and objective disorder status have
previously been found to be in high agreement for the disor-
ders included [29, 30]. Other conditions of interest including,
for example, dyslipidemia and obesity are not available in
CFAS and given the increase in prevalence of these with age-
ing it would be important to also determine the pattern of
cognitive impairments associated with each. Information on
disease severity is not available and this could impact disease-
cognition associations. Cognition was assessed using the
MMSE and CAMCOG and other batteries recommended for
testing cognition within the context of VCI-ND, such as the
Montreal Cognitive Assessment (MoCA), are not available in
CFAS. Nevertheless, using the MMSE and CAMCOG both
global and domain-speciﬁc function across multiple subdo-
mains could be assessed.
Conclusion
Identiﬁcation of VCI-ND is a challenge due to variation
in cognitive proﬁles across the different disorders and lack
of operational criteria. The ﬁndings suggest that the neuro-
psychological tests used for cognitive screening in vascular
disorders should be selected based on knowledge of the
underlying vascular condition, or where this is not known, tests
should tap as broad as domains as possible. A better under-
standing of the cognitive risks associated with different health
conditions would improve criteria for VCI-ND and help with
the development of risk models for predicting dementia in
persons with vascular disease.
Key points
• There is large variation in the cognitive proﬁles across dif-
ferent vascular disorders.
• Variation in the cognitive proﬁles of different vascular dis-
orders has implications for the development of neuro-
psychological criteria for VCI-ND.
• Poor cognitive function is a risk factor for 2-year incident
dementia in persons with hypertension, PVD, CHD, dia-
betes and stroke; with different domains associated with
dementia risk depending on the underlying condition.
• A better understanding of the cognitive risks associated
with different health conditions would improve criteria
for VCI-ND.
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